Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca co-promotes bone cancer drug

AstraZeneca is to co-promote Amgen's drug denosumab in Japan as a treatment for bone cancer disorders alongside Daiichi Sankyo

AstraZeneca is to co-promote Amgen's drug denosumab in Japan as a treatment for bone cancer disorders alongside Daiichi Sankyo.

Daiichi acquired rights to denosumab from Amgen in 2007 and filed an application for marketing authorisation in 2010. The injectable drug is currently awaiting approval from Japanese authorities.

Denosumab is the first in a new class of medicines that work by blocking a protein that activates bone-destroying cells called osteoclasts.

Amgen has decided to strike regional development and marketing deals with other big drug companies to maximise sales, and has a deal with GlaxoSmithKline (GSK) covering Europe and several big emerging markets.

Denosumab is approved in the US and Europe, under the trade name Xgeva, as a treatment for reducing fractures and other bone problems in certain cancer patients. It is also sold under the brand name Prolia for osteoporosis.

The deal does not include the osteoporosis indication, for which Daiichi also has marketing rights in Japan.

The financial terms of the agreement have not been disclosed.

24th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....

Infographics